Objective:

To explore the advancements and challenges in RNA therapeutics manufacturing, particularly focusing on the limitations of current SPOS technology and the potential of enzyme-enabled synthesis, including specific modalities and their market impact.

Key Findings:

• The RNA therapeutics market is expanding rapidly, necessitating new manufacturing solutions that address specific SPOS limitations.
• SPOS technology has significant limitations in scalability, quality, and sustainability, impacting the production of RNA therapeutics.
• Enzyme-enabled synthesis offers modularity, technical advantages, and regulatory familiarity, facilitating industry adoption and addressing SPOS challenges.

Interpretation:

The transition to enzyme-enabled RNA manufacturing represents a critical evolution in the field, significantly addressing the limitations of traditional methods while aligning with sustainability goals.

Limitations:

• Current enzyme-based methods are still in development and may face regulatory hurdles that could delay widespread adoption.
• Incremental innovations in SPOS may not fully resolve existing challenges, potentially leading to continued reliance on outdated methods.

Conclusion:

The future of RNA manufacturing lies in enzyme-enabled synthesis, which promises to enhance scalability, quality, and sustainability in the production of RNA therapeutics.